Cipla Limited — Salbutamol Exporter Profile
Indian Pharmaceutical Exporter · #1 for Salbutamol · $100.3M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Salbutamol with $100.3M in export value and 2,828 verified shipments. Cipla Limited holds a 67.4% market share in Salbutamol exports across 41 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Salbutamol Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Salbutamol?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $33.1M | 1,481 | 49.9% |
| SOUTH AFRICA | $7.4M | 284 | 11.2% |
| COLOMBIA | $4.2M | 132 | 6.4% |
| NEW ZEALAND | $3.7M | 133 | 5.7% |
| SRI LANKA | $2.9M | 170 | 4.3% |
| TURKEY | $2.5M | 72 | 3.7% |
| JORDAN | $1.8M | 56 | 2.6% |
| UNITED ARAB EMIRATES | $1.3M | 41 | 2.0% |
| UNITED KINGDOM | $940.6K | 91 | 1.4% |
| ALGERIA | $738.5K | 31 | 1.1% |
Cipla Limited exports Salbutamol to 47 countries. The largest destination is BRAZIL accounting for 49.9% of Cipla Limited's Salbutamol shipments, followed by SOUTH AFRICA (11.2%) and COLOMBIA (6.4%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Salbutamol from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| LABORATORIO TEUTO BRASILEIRO S/A | BRAZIL | $23.9M | 1,150 |
| LABORATORIO TEUTO BRASILEIRO S A | BRAZIL | $8.3M | 294 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $4.6M | 184 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $2.5M | 140 |
| PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR | TURKEY | $2.4M | 69 |
| CIPLA COLOMBIA SAS Y/O DEPOSITO UPS | COLOMBIA | $1.7M | 60 |
| REX MEDICAL LTD, | NEW ZEALAND | $1.6M | 43 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $1.2M | 32 |
| REX MEDICAL LTD | NEW ZEALAND | $1.2M | 53 |
| CIPLA COLOMBIA SAS Y O DEPOSITO UP | COLOMBIA | $1.1M | 33 |
Cipla Limited supplies Salbutamol to 119 buyers globally. The largest buyer is LABORATORIO TEUTO BRASILEIRO S/A (BRAZIL), followed by LABORATORIO TEUTO BRASILEIRO S A (BRAZIL) and MEDPRO PHARMACEUTICA (PTY) LTD (SOUTH AFRICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Salbutamol Export Value and How Much Does Cipla Limited Contribute?
India exported $130.8M worth of Salbutamol through 14,359 shipments from 602 suppliers to 164 countries, serving 1,775 buyers globally. Cipla Limited contributes $100.3M to this total, accounting for 67.4% of India's Salbutamol exports. Cipla Limited ships Salbutamol to 47 countries through 119 buyers.
What Is the Average Shipment Value for Cipla Limited's Salbutamol Exports?
Cipla Limited's average Salbutamol shipment value is $35.5K per consignment, based on 2,828 shipments totaling $100.3M. The largest destination is BRAZIL (49.9% of Cipla Limited's Salbutamol exports).
How Does Cipla Limited Compare to Other Indian Salbutamol Exporters?
Cipla Limited ranks #1 among 602 Indian Salbutamol exporters with a 67.4% market share. The top 3 exporters are CIPLA LIMITED ($100.3M), GLENMARK PHARMACEUTICALS LIMITED ($5.7M), AHLCON PARENTERALS (INDIA) LIMITED ($4.9M). Cipla Limited processed 2,828 shipments to 41 destination countries.
What Salbutamol Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| AERODINI HFA INHALER (SALBUTAMOL SULPHAT | $7.2M | 275 |
| AERODINI HFA INHALER (SALBUTAMOL PRESSURISED INHALATION 100MCG) (1 X200 MD) . | $6.0M | 162 |
| AERODINI HFA INHALER (SALBUTAMOL SULPHATE 100MCG) | $4.2M | 270 |
| AERODINI HFA INHALER (SALBUTAMOL SULPHATE 100 MCG) | $3.8M | 198 |
| AERODINI HFA INHALER SALBUTAMOL SULPHATE 100 MCG | $3.5M | 133 |
| AERODINI HFA INHALER SALBUTAMOL SULPHAT | $2.5M | 92 |
| AERODINI HFA INHALER (SALBUTAMOL SULPHATE 100 MCG)NOS | $1.8M | 204 |
| ASTHAVENT 200MD CFC FREE INHALER (SALBUTAMOL SULPHATE 100MCG) | $1.6M | 61 |
| ASTHAVENT ECOHALER (SALBUTAMOL SULPHATE INHALER 100MCG) | $1.3M | 48 |
| AERODINI HFA INHALER SALBUTAMOL PRESSURISED INHALATION 100MCG 1 X 200 MD | $1.1M | 30 |
Cipla Limited exports 517 distinct Salbutamol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is AERODINI HFA INHALER (SALBUTAMOL SULPHAT with 275 shipments worth $7.2M.
Regulatory Requirements: Exporting Salbutamol to Key Markets
What Cipla Limited must comply with to export Salbutamol to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Salbutamol Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $100.3M | 2,828 | 41 | $35.5K |
| 2 | GLENMARK PHARMACEUTICALS LIMITED | $5.7M | 298 | 11 | $19.3K |
| 3 | AHLCON PARENTERALS (INDIA) LIMITED | $4.9M | 117 | 4 | $42.1K |
Cipla Limited ranks #1 among 602 Indian Salbutamol exporters. Average shipment value of $35.5K compared to the market average of $217.4K. The closest competitors by value are GLENMARK PHARMACEUTICALS LIMITED and AHLCON PARENTERALS (INDIA) LIMITED.
Which Indian Ports Ship Salbutamol Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 2,198 | 15.3% |
| SAHAR AIR | 2,141 | 14.9% |
| DELHI AIR CARGO ACC (INDEL4) | 1,530 | 10.7% |
| NHAVA SHEVA SEA (INNSA1) | 1,497 | 10.4% |
| DELHI AIR | 1,064 | 7.4% |
| JNPT/ NHAVA SHEVA SEA | 1,036 | 7.2% |
| JNPT | 842 | 5.9% |
| Bombay Air | 568 | 4.0% |
What Other Respiratory Products Does Cipla Limited Export?
Cipla Limited also exports these respiratory products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Salbutamol Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Salbutamol, top products include Fluticasone, Amlodipine, Telmisartan, Salmeterol, Budesonide. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Salbutamol — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Salbutamol shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 2,828 individual customs records matching Cipla Limited exporting Salbutamol, covering 517 formulations to 47 countries via 119 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 164+ countries, 1,775+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Salbutamol Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Salbutamol exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Salbutamol Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Salbutamol. For current shipment-level data, contact TransData Nexus.